The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.
 
Helena Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Bristol-Myers Squibb/Roche; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Orion Clinical; Taiho Oncology; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Danny Nguyen
Honoraria - Janssen Oncology; Taiho Pharmaceutical
Consulting or Advisory Role - Black Diamond Therapeutics; Janssen Oncology
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen; Taiho Oncology
Other Relationship - Novartis; Pfizer; Seagen; Takeda
(OPTIONAL) Uncompensated Relationships - Johnson & Johnson/Janssen; Novartis; Takeda
 
Gerrina Ruiter
Consulting or Advisory Role - Boehringer Ingelheim (Inst)
Speakers' Bureau - AstraZeneca (Inst); Boehringer Ingelheim (Inst)
 
Victor Lee
Honoraria - Amgen; AQUILAB; AstraZeneca/MedImmune; Boston Scientific; Lilly; Merck; Merck Serono; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer; Pfizer; TopAlliance BioSciences Inc
Research Funding - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Ross Soo
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; J INTS BIO; J INTS BIO; Lilly; Merck; Merck Serono; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Takeda; Yuhan
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; J INTS BIO; Janssen; Lilly; Merck; Merck Serono; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Yuhan
Research Funding - AstraZeneca; Boehringer Ingelheim; Pfizer
 
Se Hyun Kim
Consulting or Advisory Role - Pfizer; Takeda
 
Daniel Tan
Honoraria - Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); Roche (Inst); Zymeworks
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Haruko Daga
Honoraria - AstraZeneca
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
James ChihHsin Yang
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Takeda
 
Antonio Passaro
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology
 
Gonzalo Fernandez Hinojal
Consulting or Advisory Role - MSD
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Oscar Juan-Vidal
Honoraria - Amgen; AstraZeneca/MedImmune; Janssen; Takeda
Consulting or Advisory Role - AstraZeneca Spain; Janssen Oncology; Lilly; Merck; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Pfizer; Roche/Genentech; Takeda
 
Sang-We Kim
No Relationships to Disclose
 
Shengting Li
Employment - Cullinan Oncology; JnJ
Leadership - Cullinan Oncoloy
Stock and Other Ownership Interests - Cullinan Oncology
 
Zhiying Cindy Xu
Stock and Other Ownership Interests - Cullinan Oncology
 
Jeffrey Jones
Employment - Cullinan Oncology
Leadership - Cullinan Oncology
Stock and Other Ownership Interests - Cullinan Oncology
 
Zofia Piotrowska
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Janssen; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Janssen; Merck; Sanofi; Taiho Oncology; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Janssen